32263-14-2

Basic information

• Product Name: 4-HYDROXY-3-METHOXY-5-METHYLBENZENECARBALDEHYDE
• Synonyms: 4-HYDROXY-3-METHOXY-5-METHYLBENZENECARBALDEHYDE;4-hydroxy-3-methoxy-5-methylbenzaldehyde
• CAS NO: 32263-14-2
• Molecular Formula: C₉H₁₀O₃
• Molecular Weight: 166.17
• Mol File: 32263-14-2.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-HYDROXY-3-METHOXY-5-METHYLBENZENECARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-3-METHOXY-5-METHYLBENZENECARBALDEHYDE(32263-14-2)
• EPA Substance Registry System: 4-HYDROXY-3-METHOXY-5-METHYLBENZENECARBALDEHYDE(32263-14-2)

Safety Data

• Hazardous Substances Data: 32263-14-2(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Synthetic Communications, 13, p. 677, 1983 DOI: 10.1080/00397918308060349

Upstream product

• 67-66-3 chloroform 
• 2896-67-5 2-methyl-6-methoxyphenol 
• 28276-04-2 3-(chloromethyl)-4-hydroxy-5-methoxybenzaldehyde 
• 37987-18-1 4-Hydroxy-3-methoxy-5-methyl-benzylalkohol 
• 100-97-0 hexamethylenetetramine 
• 60824-65-9 (4-Hydroxy-3-methoxy-5-methylbenzyl)-methylaether 
• 148-53-8 3-methoxy-2-hydroxybenzaldehyde 
• 87743-11-1 Acetic acid 2-acetoxymethyl-4-formyl-6-methoxy-phenyl ester 
• 82628-68-0 3,4-dihydroxy-5-methylbenzaldehyde 
• 74-88-4 methyl iodide 
• 121-33-5 vanillin 
• 87743-10-0 3-((dimethylamino)methyl)-4-hydroxy-5-methoxybenzaldehyde 
• 2896-66-4 2-methoxy-4,6-dimethylphenol 

Downstream Products

• 80547-77-9 3-methyl-4,5-dimethoxybenzoic acid 
• 127035-66-9 2-methoxy-6-methyl-4-[2-(thien-2-yl)ethenyl]phenol 
• 58186-50-8 4-hydroxy-3-methoxy-5-methylbenzoic acid 
• 496024-87-4 4-acetoxy-3-methoxy-5-methylbenzaldehyde 
• 62476-56-6 3-amino-2,6-dichloropyridine 
• 100668-75-5 3,4-dimethoxy-5-methylphenol 
• 1319714-04-9 1,2-dimethoxy-5-(methoxymethoxy)-3-methylbenzene 
• 1401427-20-0 C₄₂H₄₀O₁₁ 
• 80547-80-4 3,4-dimethoxy-5-methylbenzaldehyde 

Relevant articles and documents

Preparation method of 5-methyl vanillin

The invention relates to a preparation method of 5-methyl vanillin, which comprises the following steps: 1) by using ortho vanillin as a raw material, carrying out hydrogenation reduction reaction under the action of a hydrogenation catalyst to obtain 6-m

Magnetic nano-structured cobalt-cobalt oxide/nitrogen-doped carbon material as an efficient catalyst for aerobic oxidation of p-cresols

Efficient aerobic oxidation has been developed for the selective preparation of a sequence of valuable p-hydroxybenzaldehydes from corresponding p-cresols, using a new magnetically separable catalyst of nano-structured cobalt-cobalt oxide/nitrogen-doped carbon (CoOx@CN) material. CoOx@CN showed high activity for the 2-methoxy-4-cresol oxidation to vanillin, giving great yield (90%) and with good turnover number (210), as well as other p-cresols in good to great yields. The catalytic performance was investigated and related to the structural, chemical and magnetic properties which determined by scanning electron microscopy (SEM), transmission electron microscopy (TEM), X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), Fourier-transform infrared spectroscopy (FT-IR) and vibrating sample magnetometer (VSM). The effects of base to substrate molar ratio, catalyst concentration, temperature, and solvent on the conversion and selectivity patterns also have been studied. The investigation revealed that remarkable catalytic properties of CoOx@CN could be ascribed to the active species cobalt oxide, doped nitrogen and porous carbon with large surface area. The size of the catalyst is a key factor for catalyst performance. The ferromagnetic property of catalyst enables to recycle easily by an external magnetic field and reuse six successive times without significant activity loss.

2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF

Compounds of formula (II) are provided for stabilizing protein transthyretin (TTR) and inhibiting amyloid fibril formation, for example, transthyretin-mediated amyloid fibril formation, and for treating, preventing, or ameliorating one or more symptoms of amyloid diseases, for example, transthyretin-related amyloidosis (ATTR).